Drug news
NICE recommends Xgeva for as a treatment for people with bone metastases from most solid cancer tumours including Breast Cancer
The National Institute for Health and Clinical Excellence (NICE) has published final draft guidance recommending Xgeva(denosumab) from Amgen/GSK as a treatment for people with bone metastases from most solid cancer tumours.It provisionally recommends denosumab for the prevention of skeletal-related events in:
�people with bone metastases from breast cancer and
�people with bone metastases from solid tumours (other than breast or prostate) who would otherwise be prescribed bisphosphonates.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.